The Kaiser Family Foundation estimates that Aduhelm will inflict significant costs on Medicaid as it covers the Alzheimer’s treatment. In a July 13 report, the foundation claimed that with a 23.1 ...
Medicare beneficiaries could face high out-of-pocket costs to access aducanumab, a new drug the FDA approved June 7 to treat Alzheimer’s disease. Biogen and its development partner Eisai estimate that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results